Evaluation of Orlicaine by the Smile Brands Clinical Investigation Team
Spring 2024 - Evaluation of Orlicaine by the Smile Brands Clinical Investigation Team
Introduction: Orlicaine, a dental anesthetic, was subjected to a preliminary evaluation by a group of six lead general dentists over a period of at least 90 days. The purpose of this assessment was to gauge its efficacy, delivery method efficiency, cost-effectiveness, and overall acceptability among dental professionals.
Methods: Six lead general dentists, along with their respective dental hygienists, participated in the evaluation of Orlicaine. The dentists administered Orlicaine to their patients over a period of at least 90 days, with each dentist having two or more hygienists simultaneously evaluating the product. The evaluation focused on the effectiveness of Orlicaine for various dental procedures, the efficiency of its delivery method, the amount of wastage incurred, and its cost in comparison to competitors.
Results: The results of the evaluation were unanimously positive among the participating dental professionals. Orlicaine was found to be effective for all main indications as advertised in the marketing materials. Additionally, the delivery method was deemed efficient, with minimal wastage reported. One notable advantage highlighted by the participants was the cost-effectiveness of Orlicaine compared to competing products.
While the majority of providers expressed satisfaction with Orlicaine, a few noted a desire for increased viscosity in the product. However, this feedback did not constitute a major complaint and did not significantly impact the overall positive reception of Orlicaine.
Discussion: The feedback obtained from the evaluation of Orlicaine by general dentists provides valuable insights into its real-world performance and acceptability within dental practice settings. The unanimous positive feedback regarding its effectiveness, delivery method efficiency, and cost-effectiveness suggests that Orlicaine holds promise as a viable option for dental anesthesia.
Conclusion: The evaluation of Orlicaine by six lead general dentists and their hygienists yielded overwhelmingly positive results, indicating its effectiveness for various dental procedures, efficient delivery method, and favorable cost compared to competitors. While minor suggestions for product improvement were noted, they did not detract from the overall positive reception of Orlicaine. Further studies, including formal scientific testing, may be warranted to validate these preliminary findings and provide additional insights into the performance of Orlicaine in dental practice.
Declaration: The lead dentist conducting this evaluation is available as a reference and willing to address any inquiries or questions regarding the assessment of Orlicaine.
Lead Dentist from the Smile Brands Team:
Dr. Will Mcbride, DDS, PCP President
